Welcome to LookChem.com Sign In|Join Free
  • or
4-(3-benzoylthioureido)-N,N-dicyclopropyl-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

1271024-69-1

Post Buying Request

1271024-69-1 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1271024-69-1 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1271024-69-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,7,1,0,2 and 4 respectively; the second part has 2 digits, 6 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1271024-69:
(9*1)+(8*2)+(7*7)+(6*1)+(5*0)+(4*2)+(3*4)+(2*6)+(1*9)=121
121 % 10 = 1
So 1271024-69-1 is a valid CAS Registry Number.

1271024-69-1Downstream Products

1271024-69-1Relevant academic research and scientific papers

Structure-based design of selective janus kinase 2 imidazo[4,5- d ]pyrrolo[2,3- b ]pyridine inhibitors

Hart, Amy C.,Schroeder, Gretchen M.,Wan, Honghe,Grebinski, James,Inghrim, Jennifer,Kempson, James,Guo, Junqing,Pitts, William J.,Tokarski, John S.,Sack, John S.,Khan, Javed A.,Lippy, Jonathan,Lorenzi, Matthew V.,You, Dan,Mcdevitt, Theresa,Vuppugalla, Ragini,Zhang, Yueping,Lombardo, Louis J.,Trainor, George L.,Purandare, Ashok V.

, p. 845 - 849 (2015)

Early hit to lead work on a pyrrolopyridine chemotype provided access to compounds with biochemical and cellular potency against Janus kinase 2 (JAK2). Structure-based drug design along the extended hinge region of JAK2 led to the identification of an imp

Discovery of a Highly Selective JAK2 Inhibitor, BMS-911543, for the Treatment of Myeloproliferative Neoplasms

Wan, Honghe,Schroeder, Gretchen M.,Hart, Amy C.,Inghrim, Jennifer,Grebinski, James,Tokarski, John S.,Lorenzi, Matthew V.,You, Dan,Mcdevitt, Theresa,Penhallow, Becky,Vuppugalla, Ragini,Zhang, Yueping,Gu, Xiaomei,Iyer, Ramaswamy,Lombardo, Louis J.,Trainor, George L.,Ruepp, Stefan,Lippy, Jonathan,Blat, Yuval,Sack, John S.,Khan, Javed A.,Stefanski, Kevin,Sleczka, Bogdan,Mathur, Arvind,Sun, Jung-Hui,Wong, Michael K.,Wu, Dauh-Rurng,Li, Peng,Gupta, Anuradha,Arunachalam,Pragalathan, Bala,Narayanan, Sankara,Nanjundaswamy,Kuppusamy, Prakasam,Purandare, Ashok V.

supporting information, p. 850 - 855 (2015/08/24)

JAK2 kinase inhibitors are a promising new class of agents for the treatment of myeloproliferative neoplasms and have potential for the treatment of other diseases possessing a deregulated JAK2-STAT pathway. X-ray structure and ADME guided refinement of C

JAK2 INHIBITORS AND THEIR USE FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND CANCER

-

, (2011/04/14)

The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof. The formula (I) compounds inhibit tyrosine kinase activity of JAK2, thereby making them useful as antiproliferative agents for the treatment of cancer and other diseases.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 1271024-69-1